Literature DB >> 2013447

Evaluation of preoperative investigations in patients admitted for ovarian primary cytoreductive surgery.

F Guidozzi1, E W Sonnendecker.   

Abstract

Consistent with universally established practice, it has been customary in our unit to subject patients with clinically suspected or biopsy proven ovarian cancer to a large number of preoperative investigations. This is in order to determine metastases, surgical strategy, and exclusion of pelvic kidney. This study presents a comparison of the preoperative ultrasonography, computerized tomography, intravenous pyelography, chest X-ray, liver and bone scintigraphy, and barium enema results performed in 100 cases with the operative findings. These investigations were found to have marginal value in determining extent of disease, upper gastrointestinal metastatic deposits, and the need for or extent of bowel resection. It is concluded that such a standard workup, which is time-consuming and distressing for an already anxious patient, is not cost effective for a surgical procedure which is ultimately determined at laparotomy.

Entities:  

Mesh:

Year:  1991        PMID: 2013447     DOI: 10.1016/0090-8258(90)90285-s

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Endoscopic ultrasonography in the assessment of colonic wall invasion by adjacent diseases.

Authors:  N Hirata; K Kawamoto; T Ueyama; I Iwashita; K Masuda
Journal:  Abdom Imaging       Date:  1994 Jan-Feb

2.  Diagnostic accuracy of 18F-FDG PET/CT scan for peritoneal metastases in advanced ovarian cancer.

Authors:  Zheng Feng; Shuai Liu; Xingzhu Ju; Xiaojun Chen; Ruimin Li; Rui Bi; Xiaohua Wu
Journal:  Quant Imaging Med Surg       Date:  2021-08

3.  Is Routine Gastroscopy/Colonoscopy Reasonable in Patients With Suspected Ovarian Cancer: A Retrospective Study.

Authors:  Guochen Liu; Junping Yan; Shanshan Long; Zhimin Liu; Haifeng Gu; Hua Tu; Jundong Li
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.